Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

The FUTURE GB Trial has received OCTRU Green Light approval and is now open to recruitment!

Future GB logo


FUTURE-GB, an NIHR EME funded study, has opened with Southmead Hospital in Bristol as the first recruiting site.  Glioblastoma (GB) is the most common primary brain tumour and is incurable -with a poor prognosis for most patients. FUTURE-GB is a 2-stage trial, looking at the use of additional imaging technologies before and during adult glioblastoma surgery to improve patient outcomes and quality of life. Stage 1 of the trial is an IDEAL IIB study, with each patient receiving the additional imaging to ensure standardisation of practice with the technologies at each recruiting site. Stage 2 is the full randomised controlled trial, recruiting 357 participants from 15 neurosurgical centres across the UK. The whole trial will recruit for 33 months, and patient quality of life will be assessed for up to 2 years.

Similar stories

Celebrating Clinical Trials Day at NDORMS

To mark Clinical Trials Day we take a look at some of the recent developments at NDORMS and celebrate the teams that make this important area of our research programme possible.

Breakthrough in treatment for Dupuytren’s disease

Injection of the anti-TNF drug adalimumab into Dupuytren’s disease nodules is effective in reducing nodule hardness and nodule size.

Liposomal bupivacaine found to be no more effective than current treatments for post-operative knee pain

A new study published in JAMA, has found that a drug recently licensed in the UK has no effect on post-operative knee replacement recovery or pain, compared to the current treatment when administered at site of surgery.

Cemented hip replacement improves quality of life for patients over 60

The White 5 trial compared implants fixed with bone cement against uncemented implants for hip fractures treated with hemiarthroplasty.

FUTURE-GB looking ahead to 2022

FUTURE-GB has bounced into 2022 ahead of both predicted recruitment into Stage 2 (the Randomised Controlled Trial), and the sites open in Stage 2! Congratulations to all our sites for their hard work so far.